NEW YORK, NY / ACCESSWIRE / May 9, 2018 / U.S. markets posted minor changes Tuesday after President Trump announced the U.S. withdrawal from the Iran nuclear deal. The Dow Jones Industrial Average gained 0.01 percent to close at 24,360.21, while the S&P 500 Index declined 0.03 percent to close at 2,671.92. The Nasdaq Composite Index rose 0.02 percent to close at 7,266.90.
"The reason the market is not dramatically selling off is he didn't close the door to further negotiations, but he also made it clear it would be on [Trump's] terms," said Quincy Krosby, chief market strategist at Prudential Financial, according to MarketWatch.
"How far does the U.S. go with the secondary sanctions, that's the main issue for the market. You have to look at whether the market will punish the European companies who do business with Iran," said Krosby.
RDI Initiates Coverage on:
AU Optronics Corp.
AU Optronics' stock jumped 5.38% Tuesday, to close the day at $4.31. The stock recorded a trading volume of 1,443,017 shares, which was above its three months average volume of 1,072,034 shares. In the last year, AU Optronics' shares have traded in a range of 3.62 - 5.35. The share price has gained 19.06% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $4.38 is below its 200-day moving average of $4.39. Shares of the company are trading at a Price to Earnings ratio of 2.95. Shares of AU Optronics have fallen roughly 7.11 percent in the past month and are up 3.61 percent year-to-date.
Access RDI's AU Optronics Corp. Research Report at:
On Tuesday, shares of Haemonetics recorded a trading volume of 999,054 shares, which was above the three months average volume of 485,480 shares. The stock ended the day 5.79% higher at $82.55. The share price has fallen 0.18% from its 52 week high with a 52 week trading range of 38.47 - 82.70. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $75.05 is above its 200-day moving average of $65.13. Shares of Haemonetics have gained roughly 15.41 percent in the past month and are up 42.13 percent year-to-date.
Access RDI's Haemonetics Corporation Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.